A clinical trial of TATC/HT/001 as a treatment modality in hyperthyroidism.
Not Applicable
- Conditions
- Health Condition 1: E059- Thyrotoxicosis, unspecified
- Registration Number
- CTRI/2023/03/050527
- Lead Sponsor
- Ayurgenics Ayurveda Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Adult males or females,greater than or equal to 18yr age with a diagnosis of Gravesâ??disease ( Hyperthyroidism)
2.Gravesâ?? disease (Hyperthyroidism) defined as raised T4 and/or T3
3.low TSH with or without hypermetabolic symptoms
Exclusion Criteria
Pregnancy/planning pregnancy in next 01 yr, use of Antithyroid drugs, iodine containing drugs, Multinodular goiter, thyroid malignancy/suspicious nodules, significant eye disease, Refusal to give consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in TFT <br/ ><br>Changes in symptoms <br/ ><br>Changes in BMRTimepoint: Baseline to end of study ie 6 months
- Secondary Outcome Measures
Name Time Method Reduction in conventional medicine dosage <br/ ><br>Changes in Quality of life <br/ ><br>Tolerability <br/ ><br>Adverse eventsTimepoint: Baseline to end of study ie 6 months